Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Effect of fruquintinib on programmed death receptor-1 blockade antitumor immune responses in colorectal cancer.
Authors
Qingli Li
Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Qingli Li , Xiaojiao Cheng , Cong Zhou , Yao Tang , Fuli Li , Baiwen Zhang , Tinglei Huang , Jianzheng Wang , Shuiping Tu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.150
Abstract #
150
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib with PD-1 inhibitors versus fruquintinib monotherapy in late-line mCRC: A retrospective cohort study based on propensity score matching.
First Author: Tianqi An
Poster
2021 ASCO Annual Meeting
Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.
First Author: Ye Guo
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Annual Meeting
Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study.
First Author: Jiayong Liu